Logo image of ALXN

Alexion Pharm Inc (ALXN) Stock Fundamental Analysis

NASDAQ:ALXN - Nasdaq -

182.5  +3.05 (+1.7%)

After market: 183 +0.5 (+0.27%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ALXN. ALXN was compared to 558 industry peers in the Biotechnology industry. ALXN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALXN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ALXN had positive earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA 3.66%
ROE 5.48%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 9.15%
PM (TTM) 10.89%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

There is no outstanding debt for ALXN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ALXN has an Altman-Z score of 5.06. This indicates that ALXN is financially healthy and has little risk of bankruptcy at the moment.
A Debt/Equity ratio of 0.19 indicates that ALXN is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 5.06
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ALXN has a Current Ratio of 4.52. This indicates that ALXN is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.96 indicates that ALXN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 3.96

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.94% over the past year.
ALXN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.12% yearly.
ALXN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.24%.
ALXN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.44% yearly.
EPS 1Y (TTM)12.94%
EPS 3Y28.83%
EPS 5Y20.12%
EPS Q2Q%9.32%
Revenue 1Y (TTM)18.24%
Revenue growth 3Y19.57%
Revenue growth 5Y18.44%
Sales Q2Q%13.27%

3.2 Future

Based on estimates for the next years, ALXN will show a small growth in Earnings Per Share. The EPS will grow by 6.32% on average per year.
Based on estimates for the next years, ALXN will show a small growth in Revenue. The Revenue will grow by 7.94% on average per year.
EPS Next Y9.86%
EPS Next 2Y8.02%
EPS Next 3Y8.65%
EPS Next 5Y6.32%
Revenue Next Year12.08%
Revenue Next 2Y9.81%
Revenue Next 3Y8.89%
Revenue Next 5Y7.94%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALXN Yearly Revenue VS EstimatesALXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
ALXN Yearly EPS VS EstimatesALXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 14.22 indicates a correct valuation of ALXN.
ALXN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.52, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 12.48, the valuation of ALXN can be described as correct.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.58, ALXN is valued rather cheaply.
Industry RankSector Rank
PE 14.22
Fwd PE 12.48
ALXN Price Earnings VS Forward Price EarningsALXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 13.39
ALXN Per share dataALXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.44
PEG (5Y)0.71
EPS Next 2Y8.02%
EPS Next 3Y8.65%

0

5. Dividend

5.1 Amount

No dividends for ALXN!.
Industry RankSector Rank
Dividend Yield N/A

Alexion Pharm Inc

NASDAQ:ALXN (7/20/2021, 9:56:13 PM)

After market: 183 +0.5 (+0.27%)

182.5

+3.05 (+1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)02-22 2022-02-22/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners0.8%
Ins Owner Change0%
Market Cap40.34B
Analysts66.2
Price Target180.9 (-0.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 14.22
Fwd PE 12.48
P/S 6.44
P/FCF N/A
P/OCF N/A
P/B 3.24
P/tB N/A
EV/EBITDA 13.39
EPS(TTM)12.83
EY7.03%
EPS(NY)14.62
Fwd EY8.01%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS28.33
BVpS56.24
TBVpSN/A
PEG (NY)1.44
PEG (5Y)0.71
Profitability
Industry RankSector Rank
ROA 3.66%
ROE 5.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 9.15%
PM (TTM) 10.89%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 3.96
Altman-Z 5.06
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.94%
EPS 3Y28.83%
EPS 5Y20.12%
EPS Q2Q%9.32%
EPS Next Y9.86%
EPS Next 2Y8.02%
EPS Next 3Y8.65%
EPS Next 5Y6.32%
Revenue 1Y (TTM)18.24%
Revenue growth 3Y19.57%
Revenue growth 5Y18.44%
Sales Q2Q%13.27%
Revenue Next Year12.08%
Revenue Next 2Y9.81%
Revenue Next 3Y8.89%
Revenue Next 5Y7.94%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A